Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810911 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of EPO-induced Hypertension
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03810911: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT03810911 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810911, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to two factors. First, endothelial dysfunction and worsening of endothelial function from baseline to 4 weeks and second, the change of forearm blood flow in response to breathing oxygen and the change in this measure from baseline to 4 weeks. Study procedures include fasting blood draws, ambulatory blood pressure, urine collection, and forearm blood flow tests. The study hopes to accrue 160 subjects.
Interventions
- DRUG Darbepoetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810911
The ClinicalTrials.gov registry entry for NCT03810911 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darbepoetin is the first listed.
NCT03810911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03810911 about?
NCT03810911 is a clinical study titled "Mechanisms of EPO-induced Hypertension". The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to two factors. First, endoth...
What is the current status of trial NCT03810911?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2021-01-04. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT03810911?
The interventions under investigation include: Darbepoetin (DRUG).
Who is sponsoring clinical trial NCT03810911?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.